Reassessing the Cardiovascular Safety of Febuxostat: Implications of the Febuxostat versus Allopurinol Streamlined Trial

Journal article

Open access

Peer reviewed

Hyon K Choi, Tuhina Neogi, Lisa K Stamp, Robert Terkeltaub and Nicola Dalbeth

Arthritis & rheumatology (Hoboken, N.J.), Vol.73(5), pp.721-724

05/2021

Handle:

https://hdl.handle.net/10523/18201

Abstract

Allopurinol - therapeutic use

Febuxostat - therapeutic use

Gout - drug therapy

Gout Suppressants - therapeutic use

Humans

url

https://doi.org/10.1002/art.41638View

Published (Version of record) Open

15 Record Views

Record Identifier: 9926494835701891
Title: Reassessing the Cardiovascular Safety of Febuxostat: Implications of the Febuxostat versus Allopurinol Streamlined Trial
Creators: Hyon K Choi
Tuhina Neogi
Lisa K Stamp
Robert Terkeltaub
Nicola Dalbeth
Publication Details: Arthritis & rheumatology (Hoboken, N.J.), Vol.73(5), pp.721-724
Academic Unit: Medicine (UOC)
Grant note: P50 AR060772 / NIAMS NIH HHS R21 AR075990 / NIAMS NIH HHS
Date published ; e-published: 05/2021
Language: English
Resource Type ; Subtype: Journal article